Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 2,816 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more
Conditions
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia
Interventions
curcumin, cholecalciferol, laboratory biomarker analysis, pharmacological study
Drug · Dietary Supplement · Other
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Leukemia
Interventions
rituximab, cyclophosphamide, pentostatin, Alemtuzumab
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
143
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more
Conditions
Anxiety, Pediatric ALL, Procedural Anxiety
Interventions
Ketamine 100 MG/ML, Midazolam 5 MG/ML
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
2 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
Interventions
BP1001, BP1001 in combination with LDAC
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
natural killer cell therapy, cyclophosphamide, fludarabine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bryostatin 1, vincristine sulfate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
Interventions
TRX103
Biological
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Interventions
Cyclophosphamide, Fludarabine, Mesna, CliniMACS, CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Drug · Device · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Indolent or Intermediate Grade B-cell Malignancy
Interventions
Rituximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Leukemia, Lymphoma
Interventions
Forodesine Hydrochloride Sterile Solution, 5 mg/mL, Forodesine Hydrochloride Capsules (100 mg)
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • Shreveport, Louisiana • Valhalla, New York + 2 more
Conditions
Lymphoma, Quality of Life
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Compound 506U78
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Winston-Salem, North Carolina
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Interventions
Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Pentostatin, Ofatumumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphoma
Interventions
fluorine 18-fludeoxyglucose positron emission tomography
Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Leukemia, Lymphoma
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hematologic Malignancies
Interventions
Haplo HCT ≥55 years old, GVHD Prophylaxis, Haplo HCT ≥55 and < 65 years old, Haplo HCT ≥65 and ≤75 years old
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Interventions
PRT1419, Azacitidine, Venetoclax
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more
Conditions
Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions
Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer informational website
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
Tirzepatide, Resistance Exercise, Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Rituximab, Bendamustine, MEDI-551
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • La Jolla, California + 11 more